Sec Form 3 Filing - Bostjancic John J. @ Orthofix Medical Inc. - 2023-01-05

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Bostjancic John J. 2. Issuer Name and Ticker or Trading Symbol Orthofix Medical Inc. [ OFIX] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) CFO (Last) (First) (Middle) 3451 PLANO PARKWAY 3. Date of Earliest Transaction (MM/DD/YY) 01/05/2023 (Street) LEWISVILLE, TX75056 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 70,019( 1 )( 2 ) D

D Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Employee Stock Option (Right to Buy) $ 37.67 ( 3 ) 08/01/2023 Common Stock 25,810( 4 ) Employee Stock Option (Right to Buy) $ 34.09 ( 5 ) 01/27/2024 Common Stock 26,875( 6 ) D Employee Stock Option (Right to Buy) $ 43.82 ( 7 ) 01/01/2027 Common Stock 7,417( 8 ) D Employee Stock Option (Right to Buy) $ 28.85 ( 9 ) 01/01/2028 Common Stock 23,207( 10 ) D Employee Stock Option (Right to Buy) $ 23.86 ( 11 ) 04/23/2028 Common Stock 2,534( 12 ) D Employee Stock Option (Right to Buy) $ 40.5 ( 13 ) 01/28/2029 Common Stock 28,777( 14 ) D Employee Stock Option (Right to Buy) $ 30.44 ( 15 ) 02/28/2030 Common Stock 17,968( 16 ) D Employee Stock Option (Right to Buy) $ 36.04 ( 15 ) 02/28/2030 Common Stock 9,035( 17 ) D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Bostjancic John J. 3451 PLANO PARKWAY LEWISVILLE, TX75056 CFO Signatures /s/ Patrick Keran, attorney-in-fact 01/10/2023 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Includes 27,323 shares of unvested restricted stock units, of which 5,761 unvested restricted stock units vest in equal installments on each of January 28, 2023 and 2024 and 21,562 unvested restricted stock units vest in equal installments on each of February 28, 2023, 2024 and 2025. ( 2 )Acquired pursuant to the terms of the merger between the Issuer and SeaSpine Holdings Corporation ("SeaSpine") which became effective on January 5, 2023 (the "Merger"), in exchange for 168,198 shares and unvested restricted stock units of SeaSpine, shares having a market value of $22.76 per share at the effective time of the Merger. ( 3 )The option vested as to 25% of the underlying shares on May 1, 2016 and the remaining 75% vested in twelve substantially equal quarterly installments thereafter. ( 4 )The option was assumed by Issuer in connection with the Merger and replaced 62,000 SeaSpine options with an exercise price of $15.68. ( 5 )The option vested as to 25% of the underlying shares on March 31, 2016 and the remaining 75% vested in twelve substantially equal quarterly installments thereafter ( 6 )The option was assumed by Issuer in connection with the Merger and replaced 64,559 SeaSpine options with an exercise price of $14.19. ( 7 )The option vested as to 25% of the underlying shares on January 1, 2020 and the remaining 75% vested or vests, as applicable, in twelve substantially equal quarterly installments thereafter. ( 8 )The option was assumed by Issuer in connection with the Merger and replaced 17,818 SeaSpine options with an exercise price of $18.24. ( 9 )The option vested as to 25% of the underlying shares on January 1, 2021 and the remaining 75% vested or vests, as applicable, in twelve substantially equal quarterly installments thereafter. ( 10 )The option was assumed by Issuer in connection with the Merger and replaced 55,746 SeaSpine options with an exercise price of $12.01. ( 11 )The option fully vested and became exercisable on June 21, 2020. ( 12 )The option was assumed by Issuer in connection with the Merger and replaced 6,089 SeaSpine options with an exercise price of $9.93. ( 13 )The option vests as to 25% of the underlying shares on January 28, 2022 and the remaining 75% vests in twelve substantially equal quarterly installments thereafter. ( 14 )The option was assumed by Issuer in connection with the Merger and replaced 69,128 SeaSpine options with an exercise price of $16.86. ( 15 )The option vests as to 25% of the underlying shares on February 28, 2023 and the remaining 75% vests in twelve substantially equal quarterly installments thereafter. ( 16 )The option was assumed by Issuer in connection with the Merger and replaced 43,163 SeaSpine options with an exercise price of $12.67. ( 17 )The option was assumed by Issuer in connection with the Merger and replaced 21,704 SeaSpine options with an exercise price of $15.00.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.